Chardan Capital analyst Daniil Gataulin maintained a Hold rating on Outlook Therapeutics (OTLK – Research Report) today and set a price target ...

Dyne Therapeutics Inc (DYN) stock saw a modest uptick, ending the day at $14.55 which represents a slight increase of $0.42 or 2.97% from the prior close of $14.13. The stock opened at $14.3 and ...

Chardan Capital Markets has recently initiated Mind Medicine (MindMed) Inc (MNMD) stock to Buy rating, as announced on December 20, 2024, according to Finviz. Earlier, on October 14, 2024, Leerink ...

Fintel reports that on January 10, 2025, Chardan Capital initiated coverage of Unity Biotechnology (NasdaqGS:UBX) with a Buy ...

Royal Bank of Canada restated their outperform rating on shares of Lexeo Therapeutics (NASDAQ:LXEO – Free Report) in a report published on Tuesday morning,Benzinga reports. Royal Bank of Canada ...

Zura Bio Limited (NASDAQ:ZURA – Get Free Report) has been given an average rating of “Buy” by the seven ratings firms that ...

On Friday, Chardan Capital Markets began coverage of Unity Biotechnology Inc (NASDAQ:UBX) shares with a Buy rating and a $6.00 price target, representing significant upside from the current price ...

Fintel reports that on January 10, 2025, Chardan Capital initiated coverage of Unity Biotechnology (LSE:0YC0) with a Buy recommendation. There are 52 funds or institutions reporting positions in ...

Eyenovia (EYEN) has engaged Chardan as its financial advisor in connection with its evaluation of strategic alternatives. With assistance from ...

With assistance from Chardan, the Company will continue to assess a full range of strategic alternatives, including but not limited to, a business combination, sale of the Company, reverse merger ...

Eyenovia, Inc., an ophthalmic technology company, has announced it is consulting with Chardan as its financial advisor to explore various strategic alternatives, including potential business ...